News stories about CASI Pharmaceuticals (NASDAQ:CASI) have trended somewhat negative on Wednesday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a media sentiment score of -0.02 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.9909128558608 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Wei-Wu He Buys 3,086,419 Shares of CASI Pharmaceuticals Inc (CASI) Stock (americanbankingnews.com)
- HC Wainwright Thinks Diffusion Pharmaceuticals Inc’s Stock is Going to Recover – Analyst Ratings (analystratings.com)
- Here’s What to Focus on – CASI Pharmaceuticals Inc (NASDAQ: CASI) – Stocks Market Cap (stocksmarketcap.com)
- CASI Pharmaceuticals, Inc. (CASI) sticks almost 21.43% in last 5 trades – Nasdaq Fortune (press release) (nasdaqfortune.com)
- CASI Pharmaceuticals, Inc. (CASI) transacted 863799 shares unusually on Tuesday – Nasdaq Chronicle (nasdaqchronicle.com)
A number of equities analysts have recently weighed in on CASI shares. ValuEngine lowered shares of CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. HC Wainwright reissued a “buy” rating and issued a $4.50 price objective on shares of CASI Pharmaceuticals in a research report on Monday, January 29th. Finally, BidaskClub lowered shares of CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th.
In related news, Director Wei-Wu He purchased 3,086,419 shares of the company’s stock in a transaction that occurred on Monday, March 19th. The stock was purchased at an average price of $3.24 per share, with a total value of $9,999,997.56. Following the completion of the transaction, the director now owns 847,527 shares of the company’s stock, valued at approximately $2,745,987.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 24.52% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/21/casi-pharmaceuticals-casi-receives-coverage-optimism-score-of-0-02/1923771.html.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.